TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Arecor Therapeutics PLC ( (GB:AREC) ) just unveiled an announcement.
Arecor Therapeutics plc announced the grant of 230,000 options to its Chief Financial Officer, David Ellam, under the company’s Long Term Incentive Plan and All Employee Share Ownership Plan. This move is part of Arecor’s strategy to incentivize and retain key management personnel, potentially impacting the company’s operational focus and aligning management interests with shareholder value.
More about Arecor Therapeutics PLC
Arecor Therapeutics plc is a globally focused biopharmaceutical company that enhances existing therapeutic products to transform patient care. Utilizing its proprietary Arestat™ technology platform, Arecor develops a portfolio of proprietary products in diabetes and other indications, collaborating with leading pharmaceutical and biotechnology companies.
YTD Price Performance: -48.30%
Average Trading Volume: 17,913
Technical Sentiment Signal: Buy
Current Market Cap: £14.35M
For a thorough assessment of AREC stock, go to TipRanks’ Stock Analysis page.